INTRODUCTION
Epilepsy affects over 50 million people worldwide, and, for a quarter of those affected, no combination of standard therapy-primarily medications and surgery-can control their seizures. As the search for better medications and surgical approaches continues, a new avenue of epilepsy treatment is now gaining momentum; namely, implantable devices designed to predict, detect, prevent and abort seizures.
The relatively young field of neuroengineering uses engineering technology to investigate and treat neurological diseases. Epilepsy is one of this field's primary targets, along with movement disorders, stroke, affective disorders, head trauma and paralysis. Using the electrochemical properties of neurons as a foundation, 1,2 neuro engineers seek to monitor and modulate abnormal brain function by use of several novel-and often nonpharmacological-methods.
Neuroengineering research in epilepsy involves two main approaches: first, monitoring and interpretation of epileptic and potentially epileptic brain activity on multiple scales in brain networks to understand how seizures and epilepsy are generated over time; and second, the use of a creative array of approaches in order to model and manipulate the intrinsic properties of brain networks so that seizure generation can be modulated and clinical events prevented. The ultimate goal of this research is to combine these approaches into 'closed-loop' devices that feed back brain signals to control interventions that stop seizures.
This Review discusses cutting-edge strategies for devices to control epilepsy and highlights promising areas that are under active investigation. First, we will discuss the milestones that have been reached and describe some current research in seizure control devices. We will then focus on strategies for seizure prediction, a field that is less well developed and understood. Finally, we will address several central questions and challenges that remain in the field.
Despite substantial innovations in antiepileptic drug therapy over the past 15 years, the proportion of patients with uncontrolled epilepsy has not changed, highlighting the need for new treatment strategies. New implantable antiepileptic devices, which are currently under development and in pivotal clinical trials, hold great promise for improving the quality of life of millions of people with epileptic seizures worldwide. A broad range of strategies to stop seizures is currently being investigated, with various modes of control and intervention. The success of novel antiepileptic devices rests upon collaboration between neuroengineers, physicians and industry to adapt new technologies for clinical use. The initial results with these technologies are exciting, but considerable development and controlled clinical trials will be required before these treatments earn a place in our standard of clinical care.
On the basis of early neuroscience research that has shown that neural function can be recorded, manipulated and mathematically modeled, 2,3 researchers are applying new technologies to the treatment of neurological disease. These efforts closely follow the clinical success of similar approaches in cardiology, whereby analogous-albeit simplerphysiology responds dramatically to intravascular inter ventions, electrical pacing and closed-loop stimulation, through use of pacemakers, automatic implantable cardiac defibrillators, and devices that ablate arrhythmia-producing foci. For many reasons, including the complexity of neural circuits, and the relative inaccessibility of the dysfunctional regions (usually necessitating a craniotomy or similarly invasive procedure), clinical implementation of implantable brain devices continues to lag behind the cardiological applications. Nevertheless, as computing power, engineering capabilities and our knowledge of neuro physiology continue to expand, so too do the opportunities to develop clinical neuro physiological devices that can exploit this new understanding.
The field of neuroengineering is fairly new in name, although its roots extend back into the early twentieth century. Neuroengineering encompasses projects such as brain-computer interfaces to control robots or other computerized devices that can assist individuals who have paralytic injuries, 4-6 electrical stimulation of paralyzed limbs, 7 and visual prostheses that translate digital pictures from cameras into signals that can be interpreted by the brain. 8, 9 Much of this research uses computational neuroscience, which involves both the measurement and extraction of quantitative features from neurophysiological data in order to localize, decode and predict the behavior of a system. By use of mathematical models of neural function, investigators can test diagnostic and therapeutic technologies robustly before they are implemented in humans. Such computer models are particularly powerful because they can simultaneously simulate neurological function on multiple scales, which range from individual ion channels and single cell function, 10 through local networks of neurons, 11-13 to complete systems. 14,15
Applying neuroengineering to epilepsy
The mainstay of therapy for epilepsy is prophylactic treatment with antiepileptic drugs (AEDs) to prevent seizure onset. These medications work through a variety of mechanisms, often acting to suppress ion channels singly or in groups. Although more new AEDs have come to the market over the past 10 years than during any other time in history, their primary contribution has been to improve adverse effects of medication, rather than to make more people seizurefree. The proportion of people with epilepsy worldwide whose seizures cannot be controlled by medical therapy has remained unchanged during this time, at around a third. For this reason, researchers are investing increasing time and effort to develop novel approaches to treatment, such as gene therapy, 'nano particles' to target specific intra cellular targets, and anti epileptic devices.
The central clinical problem in epilepsy is that during a seizure a network of neurons in the brain becomes abnormally excitable and synchronized. Monitoring and localizing the resultant electrical discharge-the physio logical signature of seizures-forms the basis of passive recording in electroencephalography (EEG). 16 For over 50 years, EEG was the only method of monitoring functional activity in the brain. Over the past 20 years, new imaging techniques for measuring brain function have become available, including functional MRI, PET scanning, single-photon emission CT, and magneto encephalography (MEG); yet, EEG has retained its place as the most important measure available to localize epileptic neural network function. EEG performed with scalp electrodes preferentially records activity from the largest or most superficial cortical networks, owing to spatial and high-frequency filtering from the skull, scalp, cerebrospinal fluid and dura. 17 Consequently, intracranial electrodes are often required to map and track seizure generation and epileptic networks.
Since the 1970s, a growing group of researchers in neurology, neurosurgery and neuroscience has focused on actively modulating neuronal inputs and outputs to control system and network behaviors. Early attempts in this area consisted of ablative therapy-focal brain resections or lesions-to treat movement disorders such as dystonia and tremor, as well as psychiatric disease. Several years later, armed with a knowledge of local circuitry in tremor and Parkinson's disease in humans and primates, inves tigators found that focal brain stimulation could create longer lasting, reliable clinical effects without causing damage to tissue. 18-20 More than 100,000 patients have received implanted stimulators to treat movement disorders over the past few years, and these same technologies are now being applied to a variety of CNS conditions, such as depression, eating disorders, addictive behaviors and epilepsy, in an attempt to modulate and abate abnormal neural network behavior. The same principles that guided these first-generation, implantable neurodevices and their cardiac predecessors form the foundation for the newer, more-intelligent antiepileptic systems that are currently under development.
OPEN-LOOP DEVICES TO TREAT SEIZURES
The capability of an applied electric field to influence the excitability of a neuron has been known for over 40 years, 21 and it has been recognized as a potential treatment for epilepsy for over 20 years. 22 Cerebellar electrical stimulation was used in patients in the early 1970s, 23-25 with variable success. Later trials focused on stimulating specific regions in the thalamus, notably the centromedian and anterior thalamic nuclei. 26 Though limited in their statistical power, these studies supported the idea that focal brain stimula tion can be effective for controlling seizures in some patients, and indicated that these types of interventions are relatively safe. 27 These conclusions must, however, be put into perspective. Many of the early trials of brain stimulation were empirical and uncontrolled, and the few early clinical trials that were performed resulted in non-robust and often controversial findings. 25, [28] [29] [30] [31] There are many reasons for these contradictory results, not the least of which was the lack of quality-control, performance and manufacturing standards for devices, which lagged considerably behind similar government oversight and regulation for medications. For these reasons, reports of device efficacy must be treated as suggestive but inconclusive. The above studies are important, however, because they helped to pioneer the field of electrical stimulation for epilepsy, and demonstrated the need for strict research guidelines and blinded, controlled trials to test these interventions. In subsequent years, governing bodies such as the US FDA and its international counterparts have clarified the standards for demonstrating clinical safety and efficacy and the process for clinical approval of devices. 32 These standards are a breakthrough in patient care and safety. The recent clinical studies involving stimulation devices have been carefully controlled and designed, with patient safety and measurable outcomes as primary goals, 33 and the era of controlled trials in antiepileptic devices is now underway in earnest. 34 
Vagus nerve stimulation
The Vagus Nerve Stimulator (VNS; Cyberonics, Inc., Houston, TX) is the first FDA-approved device for treating epilepsy. Approved by the FDA in 1997 for adjunctive therapy in pharmacoresistant partial epilepsy, the VNS reduces the number of seizures in an individual by an average of 30-40%, although 10% or fewer patients are rendered seizure-free. 35, 36 The VNS functions through periodic electrical stimulation of the left vagus nerve by a contact wrapped around the nerve trunk in the neck (Figure 1 ). The right vagus nerve is generally avoided because stimulation on this side has the potential to cause bradyarrhythmias through stimulation of the heart's atrioventricular node. It is unclear precisely how vagus nerve stimulation modulates seizures, but the technique can promote prophylaxis against seizure occurrence, and some patients report that it can abort seizures when manually triggered in response to an epileptic aura. 37 The VNS is an 'open-loop' antiepileptic device, meaning that there is no direct feedback to modulate therapy. To deliver therapy, the device stimulates the CNS through a cranial nerve in a repetitive 'duty cycle' (e.g. on for 30 sec, then off for 5 min). Stimulation parameters are currently programmed by the physician to specify stimulation voltage, on-time, pulse-width, on-off cycle duration, and the stereotyped response when the device is triggered manually. Despite the relative simplicity of this design, which is similar to that of early cardiac pacemakers, the VNS has been found to be quite effective in some patients.
The place of vagus nerve stimulation in the armamentarium of antiepileptic therapy remains in debate. The 'response rate' to this technique, meaning the proportion of patients with a 50% or greater reduction in seizures, is comparable to that when a new AED is tried in a patient who has proven resistant to more than two medications. The VNS's side-effect profile is favorable compared with that of many AEDs currently on the market, which raises the possibility of using this therapy earlier in the disease course in individuals with seizures. In view of the greater upfront expense and greater invasiveness with the VNS compared with medications, however, first-line or secondline treatment with this device has not been attempted in extensive clinical trials to date. These issues highlight the unspoken requirement that, if market penetration and acceptance is to be high, invasive therapies must have better response rates, side-effect profiles, or both, than less-invasive or less-costly treatments. This perception is unfortunate because it can discourage certain avenues of research, and researchers need to be careful not to neglect new ideas with true scientific merit simply on account of perceived market influences.
Clinical trial: deep brain stimulation
A promising open-loop device is currently being tested in a pivotal multicenter clinical trial (the Stimulation of the Anterior Nucleus of the Thala mus in Epilepsy [SANTE] trial; Medtronic, Minnea polis, MN) for the treatment of partial-onset epilepsy. This device, known as the Kinetra® neuro stimulator (Medtronic), stimulates the anterior nucleus (AN) of the thalamus (Figure 2 ) and is similar to the deep brain stimulation (DBS) device that is used to treat Parkinson's disease (the first generation of which began as a spinal cord stimulator for chronic pain). 18 The neuro stimulator is placed stereotaxically in the left and right AN. The device stimulates the AN with a protocol that differs slightly from those used to treat Parkinson's disease and tremor, with use of intermittent rather than continuous stimu lation. 34, 38 Initially requiring two separate implantable pulse generators, one under each clavicle, the device being tested in SANTE now contains two implantable pulse generators in one device unit, implanted in only one side of the chest. The choice of the AN as a therapeutic target for this trial was made on the basis of studies in animal models of epilepsy, and two pilot trials in humans that supported the efficacy of AN stimulation for treating acute and chronic seizures. [38] [39] [40] The study was allowed to proceed past its halfway point review by its unblinded steering committee, and results of the trial are expected by the end of 2008 (N Graves, personal communication). 41, 42 Another pilot study recently showed that seizure control might be achieved if the Kinetra® device was used to stimulate the hippocampus. 43, 44 Similar open-loop strategies have been used in the subthalamic nucleus 45, 46 and the centromedian nucleus 47 in humans, and over the past 20 years many other targets have been stimulated. 48, 49 Research regarding these additional stimulation targets is still in the early stages of development and has not yet progressed to large-scale trials.
Other methods in development
Clinicians and researchers are currently developing a broad range of therapeutic antiepileptic technologies. Electric fields could prevent seizure onset in a variety of locations when applied to portions of epileptic networks. [50] [51] [52] Focal cooling takes advantage of channel dynamics, slowing down their activity to make cells less excitable, and is being implemented in animal models of epilepsy and seizures through devices such as Peltier devices, which can rapidly cool focal brain regions. [53] [54] [55] Transcranial magnetic stimulation has also been used to treat epilepsy. This technique has the benefit of permitting noninvasive, focal treatment, and it is proposed to be safe and direct; to date, however, only preliminary clinical trial data and case reports are available, [56] [57] [58] [59] some of which show disappointing results. 58 Another intriguing avenue is the use of implanted devices to elute antiepileptic medications focally. This method has been successful experimentally, but it has not yet been tested clinically. [60] [61] [62] [63] [64] For many of these methods, the next stage is to determine not only how and where to administer the treatment, but also when. It is this last question that leads to the next frontier in epilepsy technology, namely the development of closed-loop antiseizure devices.
CLOSED-LOOP DEVICES TO DETECT AND TREAT SEIZURES Clinical trial: the Responsive Neurostimulator
The design and implementation of responsive, closed-loop devices to treat seizures is an exciting new development in epilepsy therapy.
Analogous to the feedback control in automatic implantable cardiac defibrillators, closed-loop devices actively record biological signals (in this case EEG signals), process these signals in real time to detect evidence of imminent seizure onset, and then trigger an inter vention. Many devices using various strategies are currently in development, but only one, the Responsive Neurostimulator (RNS®) System (NeuroPace, Inc., Mountain View, CA; Figure 3 ), is in a pivotal clinical trial. The RNS® is a firstgeneration closed-loop device-it contains electrodes that record intracranial EEG as input to an algorithm that determines when a seizure has started or is imminent, and it triggers focal electrical stimu la tion to prevent or arrest clinical seizures. 65 An important new feature of this technology is the use of a personalized 'training period', in which the device is individually tuned to the patient after it has recorded seizures. At the end of 2007 the study was still in the recruitment phase, but preliminary results were promising. 66 
Current research: seizure prediction and second-generation closed-loop devices
Although there is great enthusiasm for closedloop devices among some investigators and industry, perhaps spurred on by the success of similarly designed cardiac devices, no study has yet demonstrated greater efficacy of first-generation, seizure-detecting closed-loop systems compared with open-loop systems. The next phase in closed-loop systems-detecting abnormalities before the seizure begins (seizure prediction)-has been an area of active research for well over a decade.
To understand the importance and potential promise of closed-loop technologies, it is important to examine the history of their development over the past 10-15 years, and to consider their relationship with the fields of seizure detection and prediction. The advent of digitized EEG recording opened up new possibilities for automated event detection for patients with epilepsy. Having a digital signal enables complex mathematical analyses, and currently available computer processors can rapidly analyze the large data streams generated by intra cranial EEG recording. Although there have been improvements in the methods to detect spikes and seizures as they occur, [67] [68] [69] [70] seizure detection algorithms are still under development, and the uncertain accuracy of these methods has been a potential roadblock for responsive antiepileptic devices. When it is accurate, seizure detection seems to be an effective feedback mechanism for closed-loop devices, to either shorten or abort clinical seizures, but there is concern that to be effective a closed-loop device might require earlier warning; one concern about the first-generation systems is that an intervention might be too late once the seizure has started. The solution to this problem could lie in seizure prediction that uses algorithms that can detect seizure precursors much earlier than is currently possible. 65, 71 Neurologists have known for a long time that some patients can predict their own seizures well in advance, and recent evidence indicates that certain subsets of patients can do this quite reliably. 72, 73 These early predictions are not always associated with discernable changes on scalp EEG or even intracranial EEG. A study conducted earlier this decade suggested that these 'preictal' changes might be undetectable either because they consist of relatively small, intermittent changes in the EEG signal, or because they occur beyond the frequency or spatial resolution of the EEG systems currently used in clinical practice. In this study, by sampling intracranial EEG in several patients at a faster rate than in typical clinical systems, objective EEG changes were identified long before a seizure occurred. 74 Although prospective seizure prediction has not yet been convincingly demonstrated, recent breakthroughs in the statistics of seizure prediction, and in our understanding of the probabilistic nature of these events, suggest that definitive evidence of statistically significant seizure prediction is imminent. [75] [76] [77] [78] The theoretical benefit of this technology with respect to antiepileptic devices is that if seizure generation can be identified long before it is manifested clinically, it is likely that the process is more spatially confined, and might be more amenable to abortive therapy, than when it involves many more neurons at the time of overt clinical onset. In addition, if seizures can be identified minutes or more before their clinical onset, there might be more opportunity to stop their progression by use of a variety of abortive and therapeutic strategies.
Over the past 10 years, many strategies for analyzing and predicting seizures have been evaluated, including many nonlinear and chaos measurements, wavelet decompositions, machine learning, and other methods. 69, 75, 76, 79 The results have been somewhat inconsistent, and to date no method has been successful in prospective tests. Many new methods are currently in development, both in private industry and through public grants. Perhaps the most important breakthrough has been the establishment of statistical methods by which to assess the success of any particular technique. 75, 76 The field has progressed from the empirical, retrospective demonstration of principles, and is now evolving into probability-based, prospective trials. Our recent understanding that seizure 'precursors' are likely to fluctuate, with variable probability of triggering an epileptic event, combined with a new statistical understanding of what constitutes successful seizure prediction and how to measure it, are among the most important developments in this field over the past 5 years.
As seizure prediction technology improves, so too does our ability to deliver moreefficient closed-loop interventions. The benefits of closed-loop devices are twofold: first, feedback enables real-time correction if the intervention is insufficient; and second, there is likely to be a reduction in the overall treatment dose, thereby reducing adverse effects and system wear. A third theoretical benefit that is unique to epilepsy is that earlier interventions (i.e. in the realm of prediction rather than during the beginning of a clinical seizure) might prevent clinical seizures from ever occurring, rather than trying to abort a de facto seizure.
One dilemma in seizure prediction is how to set the threshold for false positives. Current opinion states that a high sensitivity is preferable in order to ensure that no seizures are missed, even if stimulations are triggered for false positives. The rationale behind this approach is that responsive stimulations are selected to be harmless; that is, they are below the threshold at which tissue injury is induced, 47, 80 and the total treatment dose administered is lower than that for open-loop devices.
The essence of a closed-loop device is to deliver less-frequent-but hopefully moreeffective-interventions than open-loop devices. Several devices are currently in development, which use treatment strategies such as electrical stimulation, 81 cooling, 53 vagus nerve stimulation, 82 and localized drug delivery. 60 
FUTURE PROSPECTS
Research into the methods of predicting and treating seizures has benefited greatly from recent technological improvements. As this field moves forward, there are several important issues that need to be addressed.
Improving seizure prediction
Now that a statistical framework is available for assessment of prediction efficacy, it is possible to compare prediction methods, and later to test their utility in antiseizure devices. One popular current method focuses on extracting multiple quantitative features from the EEG signal. In this approach, various engineering methods borrowed from industry (e.g. algorithms that control web search engines, credit card fraud detection, or pattern recognition in assembly lines) can be employed to analyze EEG in an automated fashion. These systems commonly use a 'classifier' , such as a computational structure (e.g. k-nearest neighbor or fuzzy clustering), neural network or machine learning algorithm that can attempt to maximize predictability by comparing arrays of possible measures and weighted combinations of different features. In this way, the classifier removes human visualization and integration from the algorithm training process, and substitutes classification 'rules' that optimize some aspect of performance to find the best possible solutions to the detection or prediction problem. Another method is to use wavelets to identify and detect patient-specific waveforms that are found to be important to seizure generation. 83 Given the heterogeneity of causes of epilepsy, many investigators feel that it is likely that seizure detection and prediction methods will be improved if they are tuned to each individual patient. It is also likely that as the network dynamics and high-frequency data are further understood, new methods of seizure prediction will be discovered.
Electroencephalogram database
In addition to the statistical rigor necessary for predictive testing, one major hurdle to making better and more-effective anti epileptic devices is lack of access to a well-documented, organized intracranial EEG database, particularly one that includes broadband EEG data (e.g. at least a 0.1-2 kHz sampling rate). At recent NIH-sponsored seizure prediction workshops in Bethesda, MD (April 2006) and Freiburg, Germany (October 2007), sessions were dedicated to the creation of such a database, continuing from a similar discussion at the First International Collaborative Workshop on Seizure Prediction. 79 The need for an EEG database has arisen because algorithms to detect and predict seizures must be developed and tested on real clinical data, which are expensive to acquire. In addition, it is extremely important to render standard clinical data usable for clinical research, which requires the careful conditioning of data to remove artifacts, erroneous markings, and mislabeling of channels. It is necessary to have easily accessible digital storage for terabytes of data of increasing bandwidth, in a secure facility that protects patient privacy. The effort must also include a separate set of blinded 'testing EEGs' that can be used to verify methods in a quasi-prospective manner.
Defining and understanding seizures through basic research
What is a seizure? This is a fundamental-yet vital-question in seizure detection and prediction research, the answer to which is beyond the scope of this Review. Although seemingly simple on the surface, attempts to arrive at clinical, electrographic (i.e. EEG) or mechanistic definitions of this phenomenon have been elusive. This remains a crucial, active area of research for investigators studying a broad variety of epi lepsies and related topics.
Although EEG has been used to detect seizures for over 50 years, little is known about the cellular and network processes that actually produce spontaneous seizures. Slightly more is known about reflex epilepsies that are evoked by certain stimuli, such as reading, calculating, photic stimulation or unexpected somatic sensations. By contrast, the events that initiate the more-common complex partial seizures are poorly understood, except at the level of risk factors such as sleep deprivation, alcohol or certain medications. Research over the past 40 years has focused primarily on ion channels and electro physiology in both individual cells and brain slices. More recently, a wealth of genetic research has linked several ion channel mutations to specific epilepsy syndromes. 84 Comparatively little is known, however, about epilepsy on the network scalethe third spatial dimension that is eliminated in brain slice preparations. There is still much debate about even the models used to simulate epilepsy. 85 Technology is now available to evaluate epilepsy in vivo: arrays of electrodes are being used to spatially map seizure activity, 86 microwire electrode recordings can detect activity from single neurons (units) in patients with epilepsy (G Worrell, personal communication), and voltage-sensitive dyes can monitor cortical seizure activity from millions of cells simultaneously. These approaches can all provide insights into functional networks. 87 Studies in these and other areas are demonstrating seizure characteristics that are beyond the resolution of standard intracranial EEG grid and depth electrodes.
In addition to new techniques for studying seizures spatially, a wealth of new information has been obtained from sampling electrophysiological activity at higher frequency. 74 This new recording technology could potentially permit the spatial and temporal topology of seizures to be characterized, although spatial sampling is limited in humans by safety concerns and clinical necessity: at present, the intro duction of additonal electrodes is still investigational and requires institutional review and special consent from the patient. It is important to establish what recording bandwidth will be necessary and sufficient for accurate seizure detection and prediction, and on what spatial scale more-effective, second-generation implantable devices need to operate.
Investigators are now approaching epilepsy on many levels, from genes and proteins up to intact networks, and from clinical investigations with broad field potentials down to analysis of functional networks. The synergy of these new parallel efforts is now becoming apparent, and it is envisaged that the 'bottom-up' and 'top-down' approaches will meet somewhere in the middle, in the area of systems neuroscience.
What intervention can prevent a seizure?
The success of cardiac defibrillators, in exploiting cardiac physiology to eliminate deadly arrhythmias, is admirable. Is such a calculated method possible in epilepsy? The physiology of the neural network is clearly much more complex, and little is known of the network timing and topology that produces seizures. Furthermore, the brain is not amenable to the large-scale 'defibrillation' pulses that are used in the heart. Nevertheless, clear examples of effective use of antiepileptic stimulation to arrest seizures are becoming easier to find, as clinical trials of closed-loop stimulation continue. 65, 66 One strategy used by cardiac defibrillators is that of tiered intervention, in which progressively stronger electric shocks are given as the heart rhythm becomes more pathologic, or as abnormalities persist in time. Such a strategy would lend itself well to epilepsy control but to date has not been implemented in any of the devices under investigation. It is possible to imagine a scenario in which a small, asympto matic seizure-like burst on the EEG might trigger a mild localized intervention, such as an electrical stimulus. As abnormal activity becomes more widespread or longer in duration, the stimulus could become much broader spatially or more prolonged, or the amplitude could be increased. An additional step could perhaps be the introduction of another intervention, such as flooding the affected region with an AED infusion, as failure of stimulation to abort the seizure becomes clear.
Some potential drawbacks to tiered interventions are apparent. One major issue is that more-aggressive interventions are likely to produce more adverse effects. A challenge of research will be to evaluate the limits of each therapeutic intervention and their thresholds for generating adverse effects. Another issue with tiered intervention, as with all seizure inter vention strategies, is how to assess overall effective ness. Will it be sufficient simply to count the number of seizures and auras with and without intervention, as is common clinical practice for medications? It is likely that many subclinical events will be recorded by an implanted device, and this could potentially confound statistics relating to clinical efficacy if these events are not symptomatic. Further research will be required to establish the relationship between subclinical seizure data and clinical seizure control.
The currently proposed strategies for intervention in implantable antiepileptic devices are electrical stimulation, magnetic stimulation, 44 localized drug delivery, 51 and focal cooling. 71 Electrical stimulation is further divided into continuous, responsive and controlling paradigms. All three of the electrical devices currently in use or in clinical trials use periodic pulse trains; the VNS and Kinetra® devices are both continuous open-loop devices, whereas the RNS® is responsive and administers a series of up to five pulse trains on the basis of its automated interpretation of intracranial EEG activity. Pulse trains are simple to implement, and they have been remarkably successful in the DBS devices used to treat Parkinson's disease, but they are not necessarily the best stimulation method. Investigations are currently underway, by our group and others, on continuous control paradigms in which therapy is yoked to measures of preictal or ictal activity on the EEG, and in which therapy is continuously adjusted in response to the error signals between injected and recorded signals. These types of continuous control approaches, which are similar to those used in airplane autopilots and other automated systems, hold considerable theoretical promise, though it is too early to assess their effectiveness for preventing clinical seizures.
New strategies will no doubt be developed as we expand our knowledge of the complex interplay of excitation, inhibition and coupling within neural networks. Understanding this interplay will help define the cutting edge of novel antiepileptic therapy, beyond standard drug delivery. This Review only hints at the exciting and rapid developments that are underway in epilepsy research.
Personalized control
One of the primary hurdles that separates a seizure control device from a cardiac defibrillator is the heterogeneity of pathology and clinical manifestations in epilepsy. A staggering number of different pathologies can produce intractable epilepsy, including genetic causes, trauma, infection, brain malformations (such as cortical dysplasia), and medications. As a result, there is no standard, identifiable brain equivalent of basic cardiac arrhythmias such as ventricular tachycardia or atrial fibrillation. Rather, seizures are associated with an extensive range of EEG patterns. Current research with use of high-frequency recordings is now finding that many different onset patterns are also seen in the preseizure period (G Worrell, personal communication). Consequently, both detection and prediction of seizures as defined in an individual patient are difficult to generalize to all patients. As noted above, the solution might be to tune, or 'train', an antiseizure device to a particular patient. 88 Devices capable of 'learning' patterns from individuals, such as those based on machine learning or other artificial intelligence techniques, might also hold promise. To date, no clinical devices have incorporated either individ ual patient training or machine learning in an automated form, beyond the algorithms used in the NeuroPace RNS® device, which are manually trained to individual patient patterns and updated as necessary at subsequent doctor visits. One serious limitation for clinical use of current implantable device platforms has been their relatively poor memory and processing speed. Advances in technology are making the develop ment of these devices more feasible. Modern storage devices and processors are becoming increasingly capable of handling the data from EEG recording. Wireless technology also affords new opportunities, as does the potential to download information from implantable devices and transmit it over the Internet for remote processing and algorithm training. One possible option is to have wireless-capable implanted devices that can transmit prolonged data streams for offline processing and data storage.
CONCLUSIONS
First-generation antiepileptic devices are currently in pivotal clinical trials and are showing considerable promise. Motivated by the success of similarly conceived therapeutic cardiac devices, the field is poised to produce moreadvanced second-generation devices that can track seizure generation in epileptic networks, with the aim of arresting or preventing clinical events. Much of this progress has been motivated by recent technological advances at a variety of temporal and spatial levels, from molecular processes, through single cells, to functional or dysfunctional neuronal networks and broader neural systems.
The evolution of engineering technology as applied to epilepsy presents renewed promise that the periods of time when the probability of seizure onset is increased can be identified, and responsive therapy delivered to prevent epileptic events from occurring. For medication-resistant epilepsy, devices such as those discussed above present an exciting new avenue to help patients in an era when new AEDs have not markedly reduced seizure burden. Through multi disciplinary, multiscale research and collabora tion, implantable devices hold promising, exciting possibilities for diagnosis, mapping of epileptic networks, and dramatically improving therapy for epilepsy. In addition, discoveries along the way promise to greatly improve our knowledge of the mechanisms that underlie seizure generation. 
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